罗沙司他不同剂量方案对低危MDS患者疗效对比研究

Objective: To observe the effect of different doses and frequencies of roxadustat on low-risk patients with myelodysplastic syndromes (MDS). Methods: This study was conducted using a comparative treatment observation approach. Low-risk MDS patients admitted to our hospital from February 2022 to February 2023 were selected, excluding patients with a history of severe drug allergies or known allergies to roxadustat. A total of 60 patients were included and randomly divided into observation group A (20 cases, 100 mg, twice weekly), observation group B (20 cases, 50 mg, once daily), and observation group C (20 cases, 150 mg, twice weekly). Patient recovery, adverse reaction rate, and hemoglobin recovery time were compared and statistically analyzed. Results: The recovery rate of group B in the observation group was significantly higher than that in the other two groups, and the incidence of adverse reactions and the time to Hb recovery were also better in group B than in the other two groups (P<0.05). Conclusion: Low-dose, high-frequency (50 mg, once daily) administration can effectively improve the hemoglobin level of low-risk MDS patients and help improve their overall survival.